Alentis Therapeutics’ Post

How has Swiss biotech been performing in 2023? 📈 In April the Swiss Biotech Report 2024 was released and its findings were very encouraging for Switzerland's biotech landscape. 2023 marked a 50% increase in capital investment compared to 2022 and reached $2.2 billion. The industry also achieved a revenue of $8 billion in Switzerland. 💸 With public and private companies raising significant funds and Swiss contributions to the cautious yet optimistic IPO market, the country remains a leader in the industry. 🏅 Find out more in the article! ⬇️ https://lnkd.in/devcxekD #swissbiotech #SwissBiotechReport #capitalinvestment #revenuegrowth #IPO #biotechindustry #innovation #healthcare #Switzerland #biotechnews #pharma NewBiologix | Noema Pharma | Alentis Therapeutics | Rejuveron Life Sciences AG | MoonLake Immunotherapeutics (NASDAQ: MLTX) | Lonza | Oculis | CRISPR Therapeutics | Vertex Pharmaceuticals | Novartis | Roche | Flatiron Health | University of Pennsylvania

The biopharma sector is currently experiencing a shift and particular interest in artificial intelligence, with a focus on integrating these capabilities into drug discovery and development, and obesity treatments.   In 2023, the biopharma venture capital exit landscape declined from a dollar perspective to US$18.3bn versus US$23.6bn in 2022 but increased from a deal volume perspective to 94 transactions versus 77 in 2022. Exit activity over the last two years is marked by a preference for more mature clinical data compared to the market environment in 2021 which also supported exits for companies with only preliminary clinical data. Notable exits include RayzeBio's US$4.1bn acquisition by Bristol Myers Squibb and Carmot's US$2.9bn acquisition by Roche.

Stifel is proud to present “Biopharmaceutical Sector Outlook for 2024”, a publication featuring trends, themes and predictions in the biotech sector for the new year. We believe the underlying fundamentals of the biotech sector are highly attractive. Valuations remain low by historic standards, and negative investor sentiment is quickly fading away. Despite residual macro and geopolitical risks, we expect a market recovery will take place in 2024. Click below to learn more:  #biopharma #2024outlook #macroeconomics #mergersandacquisitions #IPOs

Interesting interview between Roivant CEO and BioPharma Dive.   Good discussion of M&A drivers, the obvious value of generating good clinical data for patients with unmet needs, and the capital markets. https://lnkd.in/eGD8pkdE: 2023-11-29 BioPharma Dive %5Bissue:56859%5D&utm_term=BioPharma Dive #insight #biotech #capitalraising

There are more biotechs in the marketplace competing for funds from ever more discerning investors, emphasising the need for more strategic approaches to securing funding. In part one of our two-part whitepaper series, we outline important considerations for biotech seeking funding from VCs, large pharma and other sources. Get advice and insights from industry investors and our biotech experts by downloading our whitepaper here: https://ow.ly/IQF950RrOha

The beauty of #biotech is its ability to fuel innovation for the broader biopharma industry, even amid uncertainty. In 2024, we'll see the sector’s innovation on display as the economic landscape may drive additional M&A and deals, and the opportunity for IPO may re-emerge, according to PwC. Click the article below in Fierce Biotech to read more. https://lnkd.in/eCWmJ_-C

Is the perfect wave of biotech coming our way in 2024? If so, it would bring new and exciting opportunities for VC’s, investors and the entire industry!   Despite the low number of VC investments in Germany in 2023, the life science sector has proven to be resilient.    “We see all the signals that in 2024 significantly more money will flow into biotech,” says Stefan Fischer in his latest column.    TVM Capital Life Science is well positioned to ride the wave: We pursue a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages our strategic relationship with global pharmaceutical firm, Eli Lilly and Company. We also invest in differentiated late clinical-stage therapeutics and commercial-stage medical technologies, as seen with our new portfolio additions myo and Vektor Medical, Inc. 🌟   Dive deeper into what 2024 could hold for the biotech sector by reading the full column on the Plattform Life Sciences website (in German): Die Kunst des Wellenreitens | GoingPublic.de #biotech #medtech #innovation #VentureCapital #investment 

venBio Raises $528M for Fifth Life Sciences Fund - HIT Consultant #FundingNews: venBio raises $528M for fifth life sciences fund #VentureCapital #HealthcareInvestment VenBio, a leading life sciences investment firm, has successfully raised $528 million for its fifth fund, signaling strong investor confidence in the healthcare sector. #InvestmentStrategy: Focused on transformative healthcare technologies #LifeSciences #HealthcareInnovation VenBio's investment strategy revolves around identifying and supporting companies with innovative healthcare technologies that have the potential to transform patient care and outcomes. #PortfolioCompanies: Diverse range of healthcare startups #HealthTech #Biotech The firm's portfolio includes a diverse range of healthcare startups, spanning from digital health to biotech, reflecting VenBio's commitment to supporting innovation across ai.mediformatica.com #lifescience #investment #lifesciences #biopharmaceutical #investing #investments #medical #venturecapital #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4fzHbyx)

📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of November 2023 we identify the following current VC trends in Europe: - In 2023, overall Life Sciences funding has reached EUR 8,390m - Biotech received 41% of the total investment volume (-1% compared to the previous month) - Oncology dominates as the top indication in Biotech - VectorY Therapeutics (Netherlands) has the highest transaction volume of EUR 129m in November, followed by EyeBio (United Kingdom) EUR 122m and NMD Pharma A/S (Denmark) EUR 75m - The European Innovation Council and SMEs Executive Agency (EISMEA) (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Forbion (Netherlands) and JEITO (France) - Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom) More here: https://lnkd.in/desdBhEi #VentureCapital #LifeSciences #Biotech #Pharma #MedTech #HealthTech #InvestmentTrends #Europe #FCFMonitor #HealthcareInvestment #fcffoxcorporatefinance #financingspecialist #corporatefinance #investmentbanking #capitalmarkets

Did you know that the German biotech industry recently recorded the largest M&A transaction in it's history?   ✍ In February 2024, MorphoSys signed an agreement with Novartis to be acquired for €2,7b with shareholders benefitting from a 94% premium   ...and that’s not all: The first quarter of 2024 also saw the most valuable M&A exit of a private German biotech company since 2020:    ✍ Cardior Pharmaceuticals from Hannover agreed to be acquired by Novo Nordisk for €1b   These success stories set an end to the muted M&A market and once again underscore the innovation power and international attractiveness of the German biotechnology industry.   Stay tuned for the upcoming EY German Biotech Report 2024, which will provide a comprehensive analysis of the industry's performance, along with insights into opportunities, challenges, the financing cycle and the most ground-breaking technologies.   In the meantime, join us at the upcoming Deutsche Biotechnologie-Tage, taking place on April 16 and 17 in Berlin. This event will be a great opportunity to connect and discuss the latest trends and developments of the biotech industry. We look forward to seeing you there!   Klaus Ort Dr. Kordula Becker Ulrike Kappe   #DBT2024 #Biotechnologie #Biotech